Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [16]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11059-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#11059-1-AP, RRID:AB_2124417
- Product name
- IL-13RA2 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated IL-13RA2 antibody (Cat. #11059-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, WB, ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Unveiling the expression and mechanistic role of SYCP2 in cervical lesions.
A new mechanism of arterial calcification in diabetes: interaction between H3K18 lactylation and CHI3L1.
Hyperactivity of the IL-33-ILC2s-IL-13-M-MDSCs axis promotes cervical cancer progression.
IL13RA2 promotes progression of infantile haemangioma by activating glycolysis and the Wnt/β-catenin signaling pathway.
Network pharmacology, molecular docking, and experimental verification reveal the mechanism of San-Huang decoction in treating acute kidney injury.
Correction to: Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
Neuro-oncology 2023 Sep 5;25(9):1727-1728
Identification of the α2 chain of interleukin-13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient-derived xenograft models.
In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma.
Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo.
Downregulation of Interleukin-13 Receptor α2 Inhibits Angiogenic Formation Mediated by Chitinase 3-Like 1 in Late Atherosclerotic Lesions of apoE(-/-) Mice.
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation.
Titanium nanoparticles potentially affect gingival tissue through IL-13α2 receptor expression.
Isorhamnetin Enhances the Radiosensitivity of A549 Cells Through Interleukin-13 and the NF-κB Signaling Pathway.
IL-13 and IL-13Rα1 are overexpressed in extranodal natural killer/T cell lymphoma and mediate tumor cell proliferation.
Outer brain barriers in rat and human development.
Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients.
Zhu Y, Hou Z, Wang C, Hu H, Zhang Z, Yang X, Liu L, Ren C
Discover oncology 2025 Nov 3;16(1):2002
Discover oncology 2025 Nov 3;16(1):2002
A new mechanism of arterial calcification in diabetes: interaction between H3K18 lactylation and CHI3L1.
Zhu Y, Chen JC, Zhang JL, Wang FF, Liu RP
Clinical science (London, England : 1979) 2025 Jan 29;139(2):115-130
Clinical science (London, England : 1979) 2025 Jan 29;139(2):115-130
Hyperactivity of the IL-33-ILC2s-IL-13-M-MDSCs axis promotes cervical cancer progression.
Wang B, Zhu Y, Zhang Y, Ru Z, Chen L, Zhang M, Wu Y, Ding J, Chen Z
International immunopharmacology 2025 Jan 10;144:113693
International immunopharmacology 2025 Jan 10;144:113693
IL13RA2 promotes progression of infantile haemangioma by activating glycolysis and the Wnt/β-catenin signaling pathway.
Liu Z, Ma T, Li J, Ren W, Zhang Z
Oncology research 2024;32(9):1453-1465
Oncology research 2024;32(9):1453-1465
Network pharmacology, molecular docking, and experimental verification reveal the mechanism of San-Huang decoction in treating acute kidney injury.
Liu J, Li Z, Lao Y, Jin X, Wang Y, Jiang B, He R, Yang S
Frontiers in pharmacology 2023;14:1060464
Frontiers in pharmacology 2023;14:1060464
Correction to: Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
Neuro-oncology 2023 Sep 5;25(9):1727-1728
Identification of the α2 chain of interleukin-13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient-derived xenograft models.
Nagai T, Terada N, Fujii M, Nagata Y, Nakahara K, Mukai S, Okasho K, Kamiyama Y, Akamatsu S, Kobayashi T, Iida K, Denawa M, Hagiwara M, Inoue T, Ogawa O, Kamoto T
Cancer reports (Hoboken, N.J.) 2023 Feb;6(2):e1701
Cancer reports (Hoboken, N.J.) 2023 Feb;6(2):e1701
In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma.
Wang X, Ye L, He W, Teng C, Sun S, Lu H, Li S, Lv L, Cao X, Yin H, Lv W, Xin H
Journal of controlled release : official journal of the Controlled Release Society 2022 May;345:786-797
Journal of controlled release : official journal of the Controlled Release Society 2022 May;345:786-797
Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo.
Xiong L, Lin XM, Nie JH, Ye HS, Liu J
Nanotheranostics 2021;5(2):143-154
Nanotheranostics 2021;5(2):143-154
Downregulation of Interleukin-13 Receptor α2 Inhibits Angiogenic Formation Mediated by Chitinase 3-Like 1 in Late Atherosclerotic Lesions of apoE(-/-) Mice.
Xue Q, Chen L, Yu J, Sun K, Ye L, Zheng J
Frontiers in physiology 2021;12:690109
Frontiers in physiology 2021;12:690109
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation.
Feng T, Wang J, Cheng K, Lu Q, Zhao R, Wang S, Zhang Q, Ge L, Pan J, Song G, Wang L
Cancer biology & medicine 2021 Oct 18;19(7):1008-28
Cancer biology & medicine 2021 Oct 18;19(7):1008-28
Titanium nanoparticles potentially affect gingival tissue through IL-13α2 receptor expression.
Ishikawa T, Sugawara S, Kihara H, Hanasaka T, Hatakeyama W, Sasaki M, Kondo H
Journal of oral science 2021 Jun 29;63(3):263-266
Journal of oral science 2021 Jun 29;63(3):263-266
Isorhamnetin Enhances the Radiosensitivity of A549 Cells Through Interleukin-13 and the NF-κB Signaling Pathway.
Du Y, Jia C, Liu Y, Li Y, Wang J, Sun K
Frontiers in pharmacology 2020;11:610772
Frontiers in pharmacology 2020;11:610772
IL-13 and IL-13Rα1 are overexpressed in extranodal natural killer/T cell lymphoma and mediate tumor cell proliferation.
Zhang Y, Li C, Zhang M, Li Z
Biochemical and biophysical research communications 2018 Sep 18;503(4):2715-2720
Biochemical and biophysical research communications 2018 Sep 18;503(4):2715-2720
Outer brain barriers in rat and human development.
Brøchner CB, Holst CB, Møllgård K
Frontiers in neuroscience 2015;9:75
Frontiers in neuroscience 2015;9:75
Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients.
Akiyama Y, Komiyama M, Miyata H, Yagoto M, Ashizawa T, Iizuka A, Oshita C, Kume A, Nogami M, Ito I, Watanabe R, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Yamaguchi K
Oncology reports 2014 Apr;31(4):1683-90
Oncology reports 2014 Apr;31(4):1683-90
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- HeLa cells were subjected to SDS PAGE followed by western blot with 11059-1-AP(IL13RA2,CD213A2 antibody) at dilution of 1:1000
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The IL13RA2 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human IL13RA2. This antibody recognizes human,mouse,rat antigen. The IL13RA2 antibody has been validated for the following applications: ELISA, WB, IHC analysis.
